Skip to content

Improving cognitive performance in MS by transcranial alternating current brain stimulation (tACS); a pilot study

Improving cognitive performance in MS by transcranial alternating current brain stimulation (tACS); a pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
NL-OMON
Registry ID
NL-OMON28830
Enrollment
Unknown
Registered
2017-05-09
Start date
2017-05-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis (MS)

Interventions

Transcranial alternating current stimulation (tACS) in theta range (6 Hz) applied over frontal and parietal regions synchronously

Sponsors

University Medical Center Groningen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - MS patients with subjective complaints of cognitive impairment or on the recommendation of attending neurologist; - age 30-60 years; - MRI compatible; - decreased values (1.5 standard deviations below the normative control values or below cut-off value for deviation) on at least 2 tests from NPE battery. - Diagnosis of MS according to the 2010 McDonald criteria; - No relapse in the last 3 months before the test; - Signed written informed consent; - Right handedness.

Exclusion criteria

Exclusion criteria: 1. History of psychiatric or neurological illness other than MS 2. Metal implants (e.g., pacemaker, heart valves, vascular clips, eye-implants, copper containing intra-uterine devices, non-removable piercing, cerebral implants) 3. Any risk of having metal particles in the eyes 4. Tattoos containing iron oxide (often found in red pigments) 5. (Suspected) Pregnancy or breast feeding 6. Claustrophobia 7. Alcohol or drug abuse 8. Excessive intake of coffee (>5 units per day) or alcohol (>2 units per day); 9. Recent use of alcohol (2 days before the EEG and/or fMRI measurement. 10. Recent use (within one week) of Tetrahydrocannabinol (THC) or any other nonprescription psychopharmaca; 11. Refusal to be informed of structural brain abnormalities that could be detected using MRI during the experiment 12. Diagnosis of epilepsy, or a personal or first degree family history of epileptic seizures, diagnosis of Parkinson’s disease, Myasthenia Gravis, epilepsy and dementia 13. Severe scalp skin lesions 14. Color blindness Participants are asked not to use alcohol, THC and other above mentioned medication during the course of the study.

Design outcomes

Primary

MeasureTime frame
1.Trial endpoints in coherence of EEG signal in theta range 2.Difference in reaction times on Vienna Reaction Time task.

Secondary

MeasureTime frame
1. baseline measures of cognitive performance and lesion load estimated from DTI and MTR measurements as predictors/covariates. 2.post - vs pre –stimulation Neuropsychological evaluation (NPE) scores

Contacts

Public ContactB Curcic

Antonius Deusinglaan 2

b.curcic@umcg.nl050-3616395

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)